Aldometanib (Synonyms: LXY-05-029) |
| Catalog No.GC66024 |
L'aldometanib (LXY-05-029) est un inhibiteur de l'aldolase actif par voie orale. L'aldometanib peut activer la protéine kinase activée par l'adénosine monophosphate lysosomale (AMPK) et diminuer la glycémie. L'aldometanib peut être utilisé pour la recherche de l'homéostasie métabolique.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2904601-67-6
Sample solution is provided at 25 µL, 10mM.
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis[1].
Aldometanib (0-1000 nM; 2 h) activates AMPK by preventing aldolase from binding to FBP to engender a pseudo-starvation signal[1].
Western Blot Analysis[1]
| Cell Line: | Mouse primary hepatocytes, MEFs cells |
| Concentration: | 0-1000 nM |
| Incubation Time: | 2 h |
| Result: | Activated AMPK in mouse embryonic fibroblasts (MEFs) and mouse primary hepatocytes cells. |
Immunofluorescence[1]
| Cell Line: | MEFs cells |
| Concentration: | 5 nM |
| Incubation Time: | 2 h |
| Result: | Inhibited TRPVs and induces AXIN lysosomal translocation. |
Aldometanib (oral; 0-10 mpk) reduces blood glucose in lean mice[1].
Aldometanib (oral; 2-10 mpk; twice daily; for a week) reduces blood glucose and alleviates fatty liver in obese hyperglycaemic mice[1].
Aldometanib alleviates fatty liver and nonalcoholic steatohepatitis[1].
Aldometanib (oral; 2mpk; twice-daily; for a month) alleviates liver fibrosis in NASH mice[1].
Aldometanib (oral; 0-50 μM; 0-50 days) extends lifespan in C. elegans via the lysosomal pathway[1].
| Animal Model: | Lean mice[1] |
| Dosage: | 0-10 mpk |
| Administration: | Oral |
| Result: | Decreased fasting blood glucose and improved glucose tolerance, promoted muscular TBC1D1 phosphorylation and glucose uptake. |
| Animal Model: | Obese hyperglycaemic mice[1] |
| Dosage: | 2-10 mpk |
| Administration: | Oral, twice daily, for a week |
| Result: | Decreased blood glucose, lowered blood glucose in a muscular AMPK-dependent manner reduced hepatic TAG, improved insulin sensitivity, increased glucose disposal rates, inhibited TAG synthesis in liver and primary hepatocytes, decreased fat mass. |
| Animal Model: | NASH mice[1] |
| Dosage: | 2 mpk |
| Administration: | Oral, twice-daily, for a month |
| Result: | Decreased histological scores used to describe the features of NASH, reduced apoptosis rate of hepatic cells, inhibited inflammatory responses in the liver of NASH mice and improved glucose tolerance of NASH mice. |
| Animal Model: | C. elegans[1] |
| Dosage: | 0-50 μM |
| Administration: | Oral, 0-50 days |
| Result: | Promoted oxidative stress resistance and mitochondrial functions in C. elegans. |
| Animal Model: | C57BL/6 mice[1] |
| Dosage: | 100 μg/mL |
| Administration: | Oral |
| Result: | Extended lifespan, elevated NAD?? levels and mitochondrial oxidative respiration, rejuvenated muscle function in aged mice. |
| Cas No. | 2904601-67-6 | SDF | |
| Synonymes | LXY-05-029 | ||
| Formula | C27H43Cl2IN2 | M.Wt | 593.45 |
| Solubility | DMSO: 50mg/mL | Storage | 4°C, away from moisture |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6851 mL | 8.4253 mL | 16.8506 mL |
| 5 mM | 0.337 mL | 1.6851 mL | 3.3701 mL |
| 10 mM | 0.1685 mL | 0.8425 mL | 1.6851 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *